Literature DB >> 11451841

Prognosis of patients with advanced idiopathic pulmonary fibrosis requiring mechanical ventilation for acute respiratory failure.

J B Stern1, H Mal, O Groussard, O Brugière, A Marceau, G Jebrak, M Fournier.   

Abstract

STUDY
OBJECTIVE: To evaluate the beneficial effect of mechanical ventilation (MV) in patients with idiopathic pulmonary fibrosis (IPF) who develop acute respiratory failure (ARF), with special emphasis on prognosis.
DESIGN: Retrospective study.
SETTING: Ten-bed respiratory ICU that is a part of a respiratory department actively involved in lung transplantation (LTx). PATIENTS: From 1991 to 1999, 23 patients (mean age, 52.9 years; range, 21 to 82 years) with IPF required MV for ARF. At admission to the ICU, 16 patients were potential candidates for LTx, with 5 patients already on the waiting list. MEASUREMENTS AND
RESULTS: Survival and gas exchange under MV were assessed. The precipitating cause of ARF was also analyzed. With the exception of 1 patient who successfully received a single-lung transplant 6 h after initiation of MV, all the remaining 22 patients died while receiving MV (median survival, 3 days; range, 1 h to 60 days). The duration of MV correlated positively with baseline vital capacity (percent predicted) (R = 0.54; p = 0.01) and baseline total lung capacity (percent predicted) (R = 0.71; p < 0.001), and correlated negatively with baseline PaCO(2) (R = - 0.47; p = 0.03) and the duration of evolution of IPF (R = -0.50; p = 0.01). Duration of MV did not correlate with the duration of immunosuppressive therapy (R = - 0.24; p = 0.27) or duration of oxygen therapy (R = - 0.32; p = 0.14) prior to admission. The precipitating cause of ARF was most often not identified.
CONCLUSIONS: Our data support the general belief that MV does not benefit IPF patients presenting with ARF. Initiation of MV in IPF patients is thus questionable and should, in our opinion, be restricted to patients in whom LTx can be performed within a few days after initiation of MV.

Entities:  

Mesh:

Year:  2001        PMID: 11451841     DOI: 10.1378/chest.120.1.213

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  34 in total

1.  Ventilator settings and outcome of respiratory failure in chronic interstitial lung disease.

Authors:  Evans R Fernández-Pérez; Murat Yilmaz; Hussam Jenad; Craig E Daniels; Jay H Ryu; Rolf D Hubmayr; Ognjen Gajic
Journal:  Chest       Date:  2007-11-07       Impact factor: 9.410

Review 2.  Acute exacerbations of idiopathic pulmonary fibrosis.

Authors:  Harold R Collard; Bethany B Moore; Kevin R Flaherty; Kevin K Brown; Robert J Kaner; Talmadge E King; Joseph A Lasky; James E Loyd; Imre Noth; Mitchell A Olman; Ganesh Raghu; Jesse Roman; Jay H Ryu; David A Zisman; Gary W Hunninghake; Thomas V Colby; Jim J Egan; David M Hansell; Takeshi Johkoh; Naftali Kaminski; Dong Soon Kim; Yasuhiro Kondoh; David A Lynch; Joachim Müller-Quernheim; Jeffrey L Myers; Andrew G Nicholson; Moisés Selman; Galen B Toews; Athol U Wells; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2007-06-21       Impact factor: 21.405

3.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

4.  Staging and outcome in acute exacerbation of idiopathic pulmonary fibrosis: are all limits and determinants under control?

Authors:  Antonio M Esquinas; Alejandro Ubeda Iglesias; Angela Reina González
Journal:  Lung       Date:  2014-10-14       Impact factor: 2.584

5.  What factors determine the survival of patients with an acute exacerbation of interstitial lung disease after lung cancer resection?

Authors:  Masahiro Miyajima; Atsushi Watanabe; Toshihiko Sato; Satoshi Teramukai; Masahito Ebina; Kazuma Kishi; Yukihiko Sugiyama; Haruhiko Kondo; Satoru Kobayashi; Yutaka Takahashi; Hiroyuki Ito; Ryoji Yamamoto; Shigeki Sawada; Hideki Fujimori; Kazunori Okabe; Jun Arikura; Yasushi Shintani; Hiroshige Nakamura; Shinichi Toyooka; Tohru Hasumi; Takehiro Watanabe; Yoshinobu Hata; Hisashi Iwata; Minoru Aoki; Kazuhito Funai; Shuhei Inoue; Osamu Kawashima; Tomohiko Iida; Hiroshi Date
Journal:  Surg Today       Date:  2017-11-09       Impact factor: 2.549

Review 6.  Acute exacerbation of idiopathic pulmonary fibrosis-a review of current and novel pharmacotherapies.

Authors:  Maya M Juarez; Andrew L Chan; Andrew G Norris; Brian M Morrissey; Timothy E Albertson
Journal:  J Thorac Dis       Date:  2015-03       Impact factor: 2.895

7.  Acute exacerbation of interstitial lung disease with lung cancer after surgery: evaluation with 2-[18]-fluoro-2-deoxy-D-glucose positron emission tomography.

Authors:  Tomohiro Maniwa; Masahiro Endo; Mitsuhiro Isaka; Kazuo Nakagawa; Yasuhisa Ohde; Takehiro Okumura; Haruhiko Kondo
Journal:  Surg Today       Date:  2013-09-05       Impact factor: 2.549

8.  Valuable Lung Injury Lessons From a Little Known Disease.

Authors:  Ron Leong; Maurizio Cereda
Journal:  Crit Care Med       Date:  2019-02       Impact factor: 7.598

9.  Outcomes and Mortality Prediction Model of Critically Ill Adults With Acute Respiratory Failure and Interstitial Lung Disease.

Authors:  Whitney D Gannon; David J Lederer; Mauer Biscotti; Azka Javaid; Nina M Patel; Daniel Brodie; Matthew Bacchetta; Matthew R Baldwin
Journal:  Chest       Date:  2018-01-17       Impact factor: 9.410

10.  Staging of acute exacerbation in patients with idiopathic pulmonary fibrosis.

Authors:  Tomoo Kishaba; Hitoshi Tamaki; Yousuke Shimaoka; Hajime Fukuyama; Shin Yamashiro
Journal:  Lung       Date:  2013-11-13       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.